SINGULAIR (montelukast), antileukotriene
PNEUMONOLOGY - Focus
Opinions on drugs -
Posted on
Mar 11 2016
Reason for request
Renewal of Inclusion
Actual benefit unchanged in the treatment of asthma, except in children aged 6 to 24 months where it is low
- SINGULAIR, available in three dosage strengths (4 mg, 5 mg and 10 mg), has Marketing Authorisation:
- As an add-on to corticosteroid therapy in patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom “as-needed” short-acting β2-agonists provide inadequate clinical control;
- In the prophylaxis of exercise-induced asthma;
- As an alternative treatment option to low-dose inhaled corticosteroids in patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids (only SINGULAIR 4 mg for children aged 6 months to 5 years and 5 mg for children and adolescents aged 6 to 14 years).
- Its actual benefit remains substantial in all its indications except in children aged 6 to 24 months, where it remains low.
Clinical Benefit
Substantial |
- |
Low |
Therapeutic use
- |
English version
Contact Us
Évaluation des médicaments